The importance of the physician in the generic versus trade-name prescription decision.

I examine the importance of physicians in the process by which patients receive either trade-name or generic drugs. Using a dataset on physicians, their patients, and the multisource drugs prescribed, I find that almost all physicians prescribe both types of drugs to their patients, but some physicians are more likely to prescribe generic drugs while other physicians are more likely to prescribe trade-name drugs. Very little of the prescription decision can be explained by observable characteristics of individual patients, but all of the evidence indicates that physicians are indeed an important agent in determining whether patients receive either trade-name or generic drugs.

[1]  Erwin K. Kastrup,et al.  Drug facts and comparisons , 1977 .

[2]  Jonathan Liebenau,et al.  Taking Your Medicine: Drug Regulation in the United States. , 1982 .

[3]  Y. Mundlak.  On the Pooling of Time Series and Cross Section Data , 1978 .

[4]  Robert A. Moffitt,et al.  A COMPUTATIONALLY EFFICIENT QUADRATURE PROCEDURE FOR THE ONE-FACTOR MULTINOMIAL PROBIT MODEL , 1982 .

[5]  Harold S. Luft,et al.  Health Maintenance Organizations , 1982 .

[6]  D. Dranove.  Medicaid Drug Formulary Restrictions , 1989, The Journal of Law and Economics.

[7]  W. Arthur.  Designing Economic Agents that Act Like Human Agents: A Behavioral Approach to Bounded Rationality , 1991 .

[8]  Henry G. Grabowski,et al.  Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act , 1992, The Journal of Law and Economics.

[9]  C E Phelps,et al.  Diffusion of information in medical care. , 1992, The journal of economic perspectives : a journal of the American Economic Association.

[10]  W. Manning,et al.  The demand for prescription drugs as a function of cost-sharing. , 1985, Social science & medicine.

[11]  John Kennan.  Simultaneous Equations Bias in Disaggregated Econometric Models , 1989 .

[12]  P. Doering,et al.  Therapeutic Substitution in the Health Maintenance Organization Outpatient Environment , 1988, Drug intelligence & clinical pharmacy.

[13]  Gary Chamberlain,et al.  Analysis of Covariance with Qualitative Data , 1979 .

[14]  E. Kolassa.  Physicians ' Perceptions of Prescription Drug Prices:: Their Accuracy and Effect on the Prescribing Decision , 1995 .

[15]  Richard E. Caves,et al.  Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry , 1991 .

[16]  Mark V. Pauly,et al.  Readings in the economics of contract law: The economics of moral hazard: comment , 1982 .

[17]  Milton Abramowitz,et al.  Handbook of Mathematical Functions with Formulas, Graphs, and Mathematical Tables , 1964 .

[18]  Erling B. Andersen,et al.  Conditional Inference and Models for Measuring , 1974 .

[19]  Michael Keane,et al.  A Computationally Practical Simulation Estimator for Panel Data , 1994 .

[20]  Pricing, Patent Loss and the Market for Pharmaceuticals , 1991 .

[21]  Wagner A. Kamakura,et al.  Book Review: Structural Analysis of Discrete Data with Econometric Applications , 1982 .